Sucralfate Bezoar

To the Editor: Sucralfate is a new nonsystemic agent for duodenal-ulcer disease that acts primarily by binding to the ulcer site and preventing further acid or pepsin irritation to the stomach or intestinal wall. Since sucralfate acts locally, severe side effects are usually minimal. Recently, we observed a medication bezoar related to the use of sucralfate. A 79-year-old man with Guillain–Barré syndrome was treated with 4 g of sucralfate daily for gastrointestinal bleeding secondary to peptic-ulcer disease. Because of the severity of the patient's paralysis, he required mechanical ventilation for respiratory support as well as nasogastric-tube feedings (Isocal), 100 ml . . . No extract is available for articles shorter than 400 words.